Live Breaking News & Updates on Johnson Innovative

Stay updated with breaking news from Johnson innovative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with. ....

San-diego , California , United-states , Berkeley , University-of-san-diego , Phleger-harrison , Carmine-stengone , Latham-watkins , Hollis-eden-pharmaceuticals , Clifford-chance , Nasdaq , University-of-san-diego-school-law

Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

SAN DIEGO (BUSINESS WIRE) Jun 3, 2024 ....

University-of-san-diego , California , United-states , San-diego , Berkeley , Phleger-harrison , Peter-slover , Carmine-stengone , Latham-watkins , Contineum-therapeutics-inc , Company-contacts , Tyra-biosciences-inc

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer

RYBREVANT®▼ (amivantamab) plus lazertinib shows longer
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Belgium , Hoboken , Region-flamande , Seoul , Soult-ukpyolsi , South-korea , Illinois , United-states , Chicago , Beerse , Singapore , American

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody. ....

Jersey , David-lee , Johnson , None-of-cilag-holding , Janssen-research-development , Janssen-biotech-inc , Cilag-holding , Numab-therapeutics , Global-immunology-therapeutic-area-head , Johnson-innovative , Candice-long , Worldwide-vice-president

J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal

By Denny Jacob

Johnson & Johnson entered into an agreement with Numab Therapeutics to acquire the global rights for bispecific antibody NM26 in an all-cash deal valued at $1.25 billion.

. ....

David-lee , Denny-jacob , Johnson , Numab-therapeutics , Johnson-innovative , Dow-jones ,